Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant Justicia gendarussa

  • J Nat Prod. 2017 Jun 23;80(6):1798-1807. doi: 10.1021/acs.jnatprod.7b00004.
Hong-Jie Zhang  1 Emily Rumschlag-Booms  2 Yi-Fu Guan  1 Dong-Ying Wang  1 Kang-Lun Liu  1 Wan-Fei Li  1 Van H Nguyen  3 Nguyen M Cuong  4 Djaja D Soejarto  5 Harry H S Fong  5 Lijun Rong  2
Affiliations
  • 1. School of Chinese Medicine, Hong Kong Baptist University , Kowloon, Hong Kong SAR, People's Republic of China.
  • 2. Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago , 835 South Wolcott Avenue, Chicago, Illinois 60612, United States.
  • 3. Institute of Marine Biochemistry of the Vietnam Academy of Science and Technology (VAST) , 18 Hoang Quoc Viet Road, Cau Giay, Hanoi, Vietnam.
  • 4. Cuc Phuong National Park , Nho Quan, Ninh Binh, Vietnam.
  • 5. Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago , 833 South Wood Street, Chicago, Illinois 60612, United States.
Abstract

Justicia gendarussa, a medicinal plant collected in Vietnam, was identified as a potent anti-HIV-1 active lead from the evaluation of over 4500 plant extracts. Bioassay-guided separation of the extracts of the stems and roots of this plant led to the isolation of an anti-HIV arylnaphthalene lignan (ANL) glycoside, patentiflorin A (1). Evaluation of the compound against both the M- and T-tropic HIV-1 isolates showed it to possess a significantly higher inhibition effect than the clinically used anti-HIV drug AZT. Patentiflorin A and two congeners were synthesized, de novo, as an efficient strategy for resupply as well as for further structural modification of the anti-HIV ANL glycosides in the search for drug leads. Subsequently, it was determined that the presence of a quinovopyranosyloxy group in the structure is likely essential to retain the high degree of anti-HIV activity of this type of compounds. Patentiflorin A was further investigated against the HIV-1 gene expression of the R/U5 and U5/gag transcripts, and the data showed that the compound acts as a potential inhibitor of HIV-1 reverse transcription. Importantly, the compound displayed potent inhibitory activity against drug-resistant HIV-1 isolates of both the nucleotide analogue (AZT) and non-nucleotide analogue (nevaripine). Thus, the ANL glycosides have the potential to be developed as novel anti-HIV drugs.

Products